Follow the clinical journey of extrapulmonary neuroendocrine carcinoma (EP-NEC) through a real-world patient case presented by Dr. Deepak Bhamidipati. This episode explores key diagnostic considerations, gaps in current treatment, and the need for more durable therapeutic options. Learn how emerging DLL3-targeted therapies, including the DLL3/CD3 T-cell engager, obrixtamig, are showing promise in clinical trials and may reshape the future of EP-NEC management.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Meredith Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers.
This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

With limited durable options available, new approaches are urgently needed in EP-NEC. Dr. Meredith Pelster highlights emerging therapies, including immunotherapy‑based strategies and early clinical trial data shaping future treatment directions.
This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Explore the current EP‑NEC treatment landscape, from first‑line platinum‑based therapy and etoposide to second‑line challenges. Dr. Meredith Pelster reviews guideline‑recommended options, sequencing considerations, and why clinical trials are essential in this aggressive disease.
This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Meredith Pelster introduces extrapulmonary neuroendocrine carcinoma (EP‑NEC), outlining how patients present and what distinguishes this rare disease. Learn the key elements of diagnostic workup, including pathology, imaging, and features that differentiate EP‑NEC from other neuroendocrine tumors.
This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.